PRIMARY STUDY
Vortioxetine improves illness severity for cannabis users with anxiety and depressive symptoms in a 6-month randomized controlled study
Key Findings: The group of cannabis users taking vortioxetine showed significant improvement in mood states but not in anxiety or depressive symptoms. There were no significant differences between the two groups in cannabis dependence, cognition, or functional outcomes.
Type of Study: Clinical Trial
Study Sample Size: 30
Study Result: Positive
Research Location(s): China
Year of Pub: 2025
Cannabinoids Studied: Cannabinoid (unspecified)
Phytocannabinoid Source: Not Applicable
DOSING DETAILS 
Study Dosing Objective: Effective Dose,
Established Protocol: Effective dose
Dosing Regimen: vortioxetine (mean dose 10 mg/day)
Treatment Duration: 6 months
Clinical Relevance: Vortioxetine improved mood, but not anxiety or depression in cannabis users.
Citation: Chung AKK, Tse CY, Yeung GKY, Tang SW, Chan WM, Law JKC. Vortioxetine improves illness severity for cannabis users with anxiety and depressive symptoms in a 6-month randomized controlled study. J Subst Use Addict Treat. 2025 Feb;169:209607. doi: 10.1016/j.josat.2024.209607. Epub 2024 Dec 12. PMID: 39672338.
